Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer

A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with... Int J Colorectal Dis (2009) 24:677–685 DOI 10.1007/s00384-009-0655-9 ORIGINAL ARTICLE A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer Yunfei Cao & Aihua Tan & Feng Gao & Lidan Liu & Cun Liao & Zengnan Mo Accepted: 14 January 2009 /Published online: 30 January 2009 Springer-Verlag 2009 Abstract was associated with the bevacizumab group. The two treat- Purpose Bevacizumab has demonstrated survival benefit in ment groups were similar in terms of grade 3/4 proteinuria, metastatic colorectal cancer (mCRC) patients when com- grade 3/4 leukopenia, grade 3/4 diarrhea, and the 60-day all- bined with chemotherapy. Several randomized clinical cause mortality rate. studies have evaluated bevacizumab in combination with Conclusion The addition of bevacizumab to chemotherapy chemotherapy. Meta-analysis was performed to better confers a clinically meaningful and statistically significant assess the efficacy and safety of bevacizumab with improvement in OS, PFS, and ORR. Its side effects are chemotherapy for mCRC. predictable and manageable and do not compound the Materials and methods Five clinical trials randomizing a incidence or severity of toxicities from chemotherapy. total of 3,103 mCRC patients to chemotherapy alone or to . . the combined treatment of chemotherapy plus bevacizumab Keywords http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Colorectal Disease Springer Journals

A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer

Loading next page...
 
/lp/springer-journals/a-meta-analysis-of-randomized-controlled-trials-comparing-chemotherapy-BVBa7rPsVk

References (68)

Publisher
Springer Journals
Copyright
Copyright © 2009 by Springer-Verlag
Subject
Medicine & Public Health; Proctology ; Gastroenterology ; Internal Medicine ; Surgery ; Hepatology
ISSN
0179-1958
eISSN
1432-1262
DOI
10.1007/s00384-009-0655-9
pmid
19184059
Publisher site
See Article on Publisher Site

Abstract

Int J Colorectal Dis (2009) 24:677–685 DOI 10.1007/s00384-009-0655-9 ORIGINAL ARTICLE A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer Yunfei Cao & Aihua Tan & Feng Gao & Lidan Liu & Cun Liao & Zengnan Mo Accepted: 14 January 2009 /Published online: 30 January 2009 Springer-Verlag 2009 Abstract was associated with the bevacizumab group. The two treat- Purpose Bevacizumab has demonstrated survival benefit in ment groups were similar in terms of grade 3/4 proteinuria, metastatic colorectal cancer (mCRC) patients when com- grade 3/4 leukopenia, grade 3/4 diarrhea, and the 60-day all- bined with chemotherapy. Several randomized clinical cause mortality rate. studies have evaluated bevacizumab in combination with Conclusion The addition of bevacizumab to chemotherapy chemotherapy. Meta-analysis was performed to better confers a clinically meaningful and statistically significant assess the efficacy and safety of bevacizumab with improvement in OS, PFS, and ORR. Its side effects are chemotherapy for mCRC. predictable and manageable and do not compound the Materials and methods Five clinical trials randomizing a incidence or severity of toxicities from chemotherapy. total of 3,103 mCRC patients to chemotherapy alone or to . . the combined treatment of chemotherapy plus bevacizumab Keywords

Journal

International Journal of Colorectal DiseaseSpringer Journals

Published: Jan 30, 2009

There are no references for this article.